



Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/671,995
Confirmation Number	2588
Filing Date	September 29, 2000
First Named Inventor	Ravi V.J. CHARJ
Art Unit	1643
Examiner Name	Karen A. CANELLA
Attorney Docket Number	A8873

Sheet

1

of

1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
/KAC/		JP	62-195387	A	08-28-1987	La Region Wallonne; Omnicem SA	X
/KAC/		WO	98/08506	A1	03-05-1998	Eli Lilly and Company	
/KAC/		JP	58-167592	A	10-03-1983	Takeda Chemical Industries Ltd.	X
/KAC/		JP	2003-503365	A	01-28-2003	Genentech, Inc.; Immunogen, Inc.	X
/KAC/		JP	2002-543093	A	12-17-2002	Univ. Texas System	X
/KAC/		JP	2002-541088	A	12-03-2002	Inex Pharm Corp; Univ. Texas; Texas System	X

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶

Examiner Signature

/Karen A. Canella, Ph.D./

Date Considered

07/23/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.

INFORMATION DISCLOSURE
CITATION IN AN
APPLICATION

(PTO-1449)

ATTY. DOCKET NO.
104322.198US1SERIAL NO.
09/671,995APPLICANT
Ravi V. J. CHARIFILING DATE
September 29, 2000GROUP
1642

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/KAC/	5,208,020	05/04/93	Chari et al.			07/13/92
/KAC/	5,416,064	05/16/95	Chari et al.			12/07/92
/KAC/	5,679,648	10/21/97	McCaffrey et al.			11/30/94

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/KAC/	Gupta, Radhey, S. May 5, 1985. "Cross-Resistance of Vinblastine and Taxol-Resistant Mutants of Chinese Hamster Ovary Cells to Other Anticancer Drugs." <i>Cancer Treatment Reports</i> , Vol. 69, No. 5. pp. 515-521.
/KAC/	Liu, Changnian and Ravi V. J. Chari. February 1997. "The development of antibody delivery systems to target cancer with highly potent maytansinoids." <i>Exp. Opin. Invest. Drugs</i> , Vol. 6, No. 2. pp. 169-172.
/KAC/	Chari, Ravi V. J. et al. 1992. "Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs." <i>Cancer Research, American Association for Cancer Research</i> , Vol. 52, No. 1. pp. 127-131.
/KAC/	Nakajima, Osamu, Yasuko Sugishita, Yuichi Hashimoto and Shigeo Iwasaki. 1994. "Increase in the Chemically-Induced Differentiation of Human Leukemia Cell Lines by Tubulin Disruptors." <i>Biol. Pharm. Bull.</i> Vol. 17, No. 5. pp. 742-744.
/KAC/	Liu, C., et al. "Cure of Large Human Colon Cancer Xenografts by a C242-Maytansinoid Conjugate." <i>Proceedings of the Annual Meeting of the American Association for Cancer Research</i> , Vol. 37, No. 2. pp. 466 - 467. 1995
/KAC/	Jordan, Allan, John A. Hadfield, Nicholas J. Lawrence and Alan T. McGown. "Tubulin as a Target for Anticancer Drugs: Agents Which Interact with the Mitotic Spindle." <i>Medicinal Research Reviews</i> , Vol. 18, No. 4. pp. 259-296. July 1998
/KAC/	12 July 2004. Supplementary Partial European Search Report from European Patent Application No. 00970516.1.

EXAMINER

/Karen A. Canella, Ph.D./

DATE CONSIDERED

07/23/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.